Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This study involved 30 male patients with ED, and their partners, both aged \> 18 years and in a stable heterosexual relationship (\> 6 months), seeking medical care for sexual dysfunction at Andrology Unit of University of Florence, Florence, Italy~Exclusion Criteria:~* Couples were excluded from participation if man had unstable medical conditions~* Prior pelvic surgery or trauma~* Spinal cord injury~* Prostate surgery or radiation~* Diabetes mellitus~* Neurogenic trauma~* Retinitis pigmentosa~* Peyronie's disease~* Multiple sclerosis~* Substance abuse disorder~* Significant mental health problems requiring psychotropic drugs, or were receiving medication for heart disease/angina (especially nitrates) or vascular disease.~* Testosterone levels has been considered normal for plasma levels ≥ 12 nmol/L and/or calculated free testosterone≥ 225 pmol/L.~* When a diagnosis of hypogonadism was made, an adequate testosterone replacement therapy was assessed.~* Patients with an artheriogenic ED (assessed with peak systolic velocity at penile colour doppler ultrasound after PGE1 stimulation, considered normal for data ≥ 25 cm/sec ) were excluded.~* We also excluded couples including women with primary sexual dysfunction, as dyspareunia, anorgasmia or vaginismus; substance abuse disorder and/or with significant mental health problems requiring psychotropic drugs.~* The presence of substance abuse or mental health problems was assessed by clinical interviews by a mental health specialist.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vardenafil (Type: ACTIVE_COMPARATOR): The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
- vardenafil+cbst (Type: ACTIVE_COMPARATOR): The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings.

Based on this trial design, predict the completion outcome and termination type (if applicable).